Quantcast
Last updated on April 20, 2014 at 13:20 EDT

WuXi PharmaTech Honored on the Deloitte Technology Fast 500 Asia Pacific 2008 List for the Fifth Consecutive Year

February 8, 2009

SHANGHAI, China, Feb. 8 /PRNewswire-Asia/ — WuXi PharmaTech (NYSE: WX), a
leading pharmaceutical, biotechnology and medical device research and
development outsourcing company with operations in China and the United
States
, is proud to announce that it was selected for the Deloitte Technology
Fast 500 Asia Pacific 2008 list for the fifth consecutive year. The Deloitte
program recognizes technology companies in the Asia Pacific region that have
achieved the fastest rates of annual revenue growth during the past three
years. WuXi PharmaTech is one of only 13 companies to be so recognized for
five years in a row and the only such company in China.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

“Achieving our place in this ranking of Asia Pacific’s elite growth
companies is recognition of our successful business model,” commented Mr.

Benson Tsang, Chief Financial Officer of WuXi PharmaTech. “Our business is
built around an intense focus on meeting the needs of our biopharmaceutical
and medical device partners to improve R&D productivity. We are continuing to
make steady progress in expanding our service portfolio to provide a global,
fully integrated, high-quality R&D service platform. Our ongoing work to
begin GLP toxicology operations in Suzhou, in what will be the largest such
facility in China, and to integrate WuXi operations with those of U.S.-based
AppTec Laboratory Services, Inc., represent important milestones in that
effort.”

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical
device R&D outsourcing company, with operations in China and the United
States
. As a research-driven and customer-focused company, WuXi PharmaTech
provides pharmaceutical, biotechnology, and medical device companies with a
broad and integrated portfolio of laboratory and manufacturing services
throughout the drug and medical device R&D process. WuXi PharmaTech’s
services are designed to assist its global partners in shortening the cycle
and lowering the cost of drug and medical device R&D. The operating
subsidiaries of WuXi PharmaTech are known as WuXi AppTec. For more
information, please visit: http://www.wuxiapptec.com .

    For more information, please contact:

     Ronald Aldridge
     Director of Investor Relations
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +1-215-218-5515
     Email: ir@wuxiapptec.com

SOURCE WuXi PharmaTech (Cayman) Inc.


Source: newswire